{"id":"oxandrolone","rwe":[{"pmid":"41620041","year":"2026","title":"Effects of repeated administration of oxandrolone in female wistar rats undergoing strength training.","finding":"","journal":"The Journal of steroid biochemistry and molecular biology","studyType":"Clinical Study"},{"pmid":"41546595","year":"2026","title":"Androgen Use Among Female Amateur Athletes: A Retrospective Analysis.","finding":"","journal":"Scandinavian journal of medicine & science in sports","studyType":"Clinical Study"},{"pmid":"41386665","year":"2026","title":"Manhole Sampling at Gyms and Sports Centers in Denmark: A Pilot Study Using Wastewater Analysis as a Tool for Monitoring the Use of Performance-Enhancing Drugs.","finding":"","journal":"Drug testing and analysis","studyType":"Clinical Study"},{"pmid":"41366311","year":"2025","title":"Post-COVID-19 subacute painless thyroiditis: a case report in an anabolic androgenic steroid user.","finding":"","journal":"BMC infectious diseases","studyType":"Clinical Study"},{"pmid":"41298796","year":"2025","title":"Comparative effects of respiratory stimulants in mechanically ventilated patients: a network meta-analysis of randomized controlled trials.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"tags":[{"label":"oxandrolone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Androgen receptor","category":"target"},{"label":"AR","category":"gene"},{"label":"A14AA08","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Catabolic Process","category":"indication"},{"label":"Crealta Pharms Llc","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anabolic Agents","category":"pharmacology"},{"label":"Androgens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":77.383,"date":"","count":11,"signal":"Testicular atrophy","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=77)"},{"llr":62.289,"date":"","count":9,"signal":"Muscle mass","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=62)"},{"llr":52.628,"date":"","count":12,"signal":"Hereditary angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=53)"},{"llr":50.351,"date":"","count":9,"signal":"Myocardial fibrosis","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=50)"},{"llr":42.962,"date":"","count":8,"signal":"Cardiac death","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=43)"},{"llr":40.877,"date":"","count":20,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=41)"},{"llr":37.01,"date":"","count":8,"signal":"Prescription drug used without a prescription","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=37)"}],"drugInteractions":[{"url":"/drug/warfarin","drug":"warfarin","action":"Avoid combination","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Acne","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Gynecomastia","drugRate":"","severity":"common","organSystem":""},{"effect":"Menstrual irregularities","drugRate":"","severity":"common","organSystem":""},{"effect":"Clitoral enlargement","drugRate":"","severity":"common","organSystem":""},{"effect":"Phallic enlargement","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased frequency or persistence of erections","drugRate":"","severity":"common","organSystem":""},{"effect":"Hirsutism","drugRate":"","severity":"common","organSystem":""},{"effect":"Male pattern baldness in females","drugRate":"","severity":"common","organSystem":""},{"effect":"Deepening of the voice in females","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Changes in libido","drugRate":"","severity":"common","organSystem":""},{"effect":"Excitation","drugRate":"","severity":"common","organSystem":""},{"effect":"Habituation","drugRate":"","severity":"common","organSystem":""},{"effect":"Retention of serum electrolytes","drugRate":"","severity":"common","organSystem":""},{"effect":"Decreased glucose tolerance","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased creatinine excretion","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased serum levels of creatinine phosphokinase","drugRate":"","severity":"common","organSystem":""},{"effect":"Inhibition of gonadotropin secretion","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Arteriosclerotic vascular disease","Benign prostatic hyperplasia","Blood coagulation disorder","Breast Carcinoma in Males","Breastfeeding (mother)","Cholestatic hepatitis","Disease of liver","Disorder of coronary artery","Edema","Heart failure","Hypercalcemia","Hypercholesterolemia","Hypoalphalipoproteinemia","Kidney disease","Neoplasm of liver","Neoplasm of prostate","Nephrotic syndrome","Peliosis hepatis","Pregnancy, function"],"specialPopulations":{"Pregnancy":"Teratogenic effects. (see CONTRAINDICATIONS).","Geriatric use":"Oxandrolone, at daily doses of mg bid and 10 mg bid, was evaluated in four clinical trials involving total of 339 patients with different underlying medical conditions. The maximum duration of treatment was months with the average duration of treatment from 68.5 days to 94.7 days across the studies. total of 172 elderly patients (>= 65 years of age) received oxandrolone treatment. Mean weight gain was similar in those >= 65 and those 65 years of age. No significant differences in ","Paediatric use":"Anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children and the effect may continue for months after the drug has been stopped. Therefore, therapy should be monitored by x-ray studies at 6-month intervals in order to avoid the risk of compromising adult height. Androgenic anabolic steroid therapy should be used very cautiously in children and only by specialists who are aware of the effects on bone maturation (see WARNINGS)."},"seriousAdverseEvents":[{"effect":"Cholestatic jaundice with hepatic necrosis and death","drugRate":"","severity":"serious"},{"effect":"Hepatocellular neoplasms","drugRate":"","severity":"serious"},{"effect":"Peliosis hepatis","drugRate":"","severity":"serious"},{"effect":"Testicular atrophy","drugRate":"","severity":"serious"},{"effect":"Oligospermia","drugRate":"","severity":"serious"},{"effect":"Chronic priapism","drugRate":"","severity":"serious"},{"effect":"Premature closure of epiphyses in children","drugRate":"","severity":"serious"},{"effect":"Bleeding in patients on concomitant anticoagulant therapy","drugRate":"","severity":"serious"},{"effect":"Masculinization of the fetus","drugRate":"","severity":"serious"},{"effect":"Inhibition of testicular function","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Crealta Pharms Llc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OXANDROLONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:42:17.082976+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:42:23.914247+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXANDROLONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:42:24.313559+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:42:25.381765+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200436/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:42:25.043995+00:00"}},"allNames":"oxandrin","offLabel":[],"synonyms":["oxandrolone","anavar","lonavar","oxandren","oxandrin","vasorome"],"timeline":[{"date":"1964-07-21","type":"positive","source":"DrugCentral","milestone":"FDA approval (Crealta Pharms Llc)"},{"date":"2006-12-01","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Oxandrin (oxandrolone) is a small molecule anabolic steroid that targets the androgen receptor. It was originally developed by CREALTA PHARMS LLC in 1964 and is currently owned by the same company. Oxandrin is used to treat catabolic processes and has a bioavailability of 97% with a half-life of 13.3 hours. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its potential for liver toxicity and cardiovascular side effects.","approvals":[{"date":"1964-07-21","orphan":false,"company":"CREALTA PHARMS LLC","regulator":"FDA"}],"brandName":"Oxandrin","ecosystem":[{"indication":"Catabolic Process","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Androgen receptor","novelty":"Follow-on","targets":[{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"}],"modality":"Small Molecule","drugClass":"oxandrolone","explanation":"","oneSentence":"","technicalDetail":"Oxandrolone is a non-aromatizable, 17-alpha-alkylated anabolic steroid that selectively binds to the androgen receptor, promoting an increase in protein synthesis and a decrease in protein degradation, ultimately leading to muscle growth and repair."},"commercial":{"launchDate":"1964","_launchSource":"DrugCentral (FDA 1964-07-21, CREALTA PHARMS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2011","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OXANDROLONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXANDROLONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:12:46.269292","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:42:26.583036+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"stanozolol","drugSlug":"stanozolol","fdaApproval":"1962-01-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"oxymetholone","drugSlug":"oxymetholone","fdaApproval":"1972-01-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"prasterone","drugSlug":"prasterone","fdaApproval":"","patentExpiry":"Mar 19, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"oxandrolone","indications":{"approved":[{"name":"Catabolic Process","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Prolonged administration of corticosteroids"}],"offLabel":[{"name":"Turner syndrome","source":"DrugCentral","drugName":"OXANDROLONE","evidenceCount":138,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"stanozolol","brandName":"stanozolol","genericName":"stanozolol","approvalYear":"1962","relationship":"same-class"},{"drugId":"oxymetholone","brandName":"oxymetholone","genericName":"oxymetholone","approvalYear":"1972","relationship":"same-class"},{"drugId":"prasterone","brandName":"prasterone","genericName":"prasterone","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05893069","phase":"PHASE4","title":"Oxandrolone Multiligament Knee","status":"SUSPENDED","sponsor":"George F. Hatch","startDate":"2023-07-01","conditions":["Ligament Tear Knee"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT06974526","phase":"PHASE2","title":"Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction","status":"RECRUITING","sponsor":"Science Valley Research Institute","startDate":"2025-11-28","conditions":["Anterior Cruciate Ligament (ACL) Reconstruction"],"enrollment":96,"completionDate":"2027-04-30"},{"nctId":"NCT03091075","phase":"NA","title":"Oxandrolone Rotator Cuff Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-09-23","conditions":["Rotator Cuff Tear"],"enrollment":116,"completionDate":"2025-12"},{"nctId":"NCT04090697","phase":"PHASE1,PHASE2","title":"Use of Oxandrolone to Promote Growth in Infants With HLHS","status":"TERMINATED","sponsor":"Carelon Research","startDate":"2019-12-20","conditions":["Hypoplastic Left Heart","Congenital Heart Disease"],"enrollment":34,"completionDate":"2023-09-19"},{"nctId":"NCT05516849","phase":"PHASE3","title":"Placebo Versus Oxandrolone Supplementation in Trauma","status":"WITHDRAWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-05-19","conditions":["Trauma Injury"],"enrollment":0,"completionDate":"2023-08-03"},{"nctId":"NCT00673309","phase":"PHASE2,PHASE3","title":"Assessment of Mechanisms of Improved Wound Healing","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2000-07","conditions":["Burns"],"enrollment":644,"completionDate":"2013-04"},{"nctId":"NCT00070148","phase":"PHASE3","title":"Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2004-03-01","conditions":["Unspecified Adult Solid Tumor, Protocol Specific","Weight Changes"],"enrollment":155,"completionDate":"2007-08-01"},{"nctId":"NCT00348946","phase":"PHASE2","title":"Androgen Effect on Klinefelter Syndrome Motor Outcome","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-07","conditions":["Klinefelter Syndrome"],"enrollment":93,"completionDate":"2017-11-30"},{"nctId":"NCT01048632","phase":"PHASE1","title":"Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants","status":"COMPLETED","sponsor":"University of Utah","startDate":"2010-07","conditions":["Malnutrition"],"enrollment":20,"completionDate":"2016-05"},{"nctId":"NCT00675714","phase":"PHASE2,PHASE3","title":"Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2004-01","conditions":["Burns"],"enrollment":1126,"completionDate":"2019-07-15"},{"nctId":"NCT02047552","phase":"PHASE2","title":"RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone","status":"WITHDRAWN","sponsor":"Denver Health and Hospital Authority","startDate":"2015-01","conditions":["Functional Iron Deficiency","Trauma","Anemia"],"enrollment":0,"completionDate":"2017-12"},{"nctId":"NCT03218631","phase":"PHASE1","title":"Oxandrolone in Healthy Adults: A Relative Bioavailability Study","status":"COMPLETED","sponsor":"University of Utah","startDate":"2017-07-10","conditions":["Bioavailability"],"enrollment":6,"completionDate":"2017-11-30"},{"nctId":"NCT00001343","phase":"PHASE2","title":"The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1992-12-11","conditions":["Dwarfism","Turner's Syndrome"],"enrollment":80,"completionDate":"2007-10-10"},{"nctId":"NCT00027391","phase":"NA","title":"Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"2001-09","conditions":["Muscular Dystrophies"],"enrollment":160,"completionDate":"2004-08"},{"nctId":"NCT00101361","phase":"PHASE3","title":"Oxandrolone to Heal Pressure Ulcers","status":"TERMINATED","sponsor":"US Department of Veterans Affairs","startDate":"2005-08","conditions":["Pressure Ulcer"],"enrollment":212,"completionDate":"2008-12"},{"nctId":"NCT00029159","phase":"PHASE3","title":"The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"1992-11","conditions":["Turner Syndrome"],"enrollment":200,"completionDate":"2012-06"},{"nctId":"NCT00243399","phase":"PHASE1","title":"Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-07","conditions":["Fanconi Anemia"],"enrollment":10,"completionDate":"2010-01"},{"nctId":"NCT00006167","phase":"PHASE4","title":"Nutrition Intervention in AIDS Wasting","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1998-01","conditions":["HIV Wasting Syndrome"],"enrollment":0,"completionDate":"2000-08"},{"nctId":"NCT00004275","phase":"PHASE2","title":"Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1999-10","conditions":["Turner's Syndrome"],"enrollment":80,"completionDate":""},{"nctId":"NCT00652886","phase":"PHASE1","title":"Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2005-03","conditions":["To Determine the Bioequivalence Under Fasting Conditions"],"enrollment":26,"completionDate":"2005-06"},{"nctId":"NCT00223769","phase":"NA","title":"The Use of Anabolic Steroids to Improve Function After Spinal Cord Injury","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2004-01","conditions":["Spinal Cord Injury"],"enrollment":40,"completionDate":"2006-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Oxandrolone"},{"form":"TABLET","route":"ORAL","productName":"oxandrolone"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146464","MMSL":"4491","NDDF":"001258","UNII":"7H6TM3CT4L","VUID":"4018126","CHEBI":"CHEBI:7820","VANDF":"4018126","INN_ID":"1325","RXNORM":"224933","UMLSCUI":"C0029995","chemblId":"CHEMBL1200436","ChEMBL_ID":"CHEMBL1200436","KEGG_DRUG":"D00462","DRUGBANK_ID":"DB00621","PUBCHEM_CID":"5878","SNOMEDCT_US":"126128007","IUPHAR_LIGAND_ID":"7092","MESH_DESCRIPTOR_UI":"D010074"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1964-","companyName":"Crealta Pharms Llc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"FDA label","halfLife":"13.3 hours","bioavailability":"97%"},"publicationCount":530,"therapeuticAreas":["Bone"],"atcClassification":{"source":"DrugCentral","atcCode":"A14AA08","allCodes":["A14AA08"]},"biosimilarFilings":[],"originalDeveloper":"Crealta Pharms Llc","recentPublications":[{"date":"2026 Apr","pmid":"41620041","title":"Effects of repeated administration of oxandrolone in female wistar rats undergoing strength training.","journal":"The Journal of steroid biochemistry and molecular biology"},{"date":"2026 Jan","pmid":"41546595","title":"Androgen Use Among Female Amateur Athletes: A Retrospective Analysis.","journal":"Scandinavian journal of medicine & science in sports"},{"date":"2026 Mar","pmid":"41386665","title":"Manhole Sampling at Gyms and Sports Centers in Denmark: A Pilot Study Using Wastewater Analysis as a Tool for Monitoring the Use of Performance-Enhancing Drugs.","journal":"Drug testing and analysis"},{"date":"2025 Dec 9","pmid":"41366311","title":"Post-COVID-19 subacute painless thyroiditis: a case report in an anabolic androgenic steroid user.","journal":"BMC infectious diseases"},{"date":"2025 Nov 26","pmid":"41298796","title":"Comparative effects of respiratory stimulants in mechanically ventilated patients: a network meta-analysis of randomized controlled trials.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturers":4,"_genericFilersChecked":true,"genericManufacturerList":["Par Pharm","Roxane","Sandoz","Upsher Smith Labs"],"status":"approved","companyName":"Crealta Pharms Llc","companyId":"crealta-pharms-llc","modality":"Small molecule","firstApprovalDate":"1964","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1964-07-21T00:00:00.000Z","mah":"CREALTA PHARMS LLC","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:42:26.583036+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}